CREATE Medicines to Present Clinical Progress at Jefferies Global Healthcare Conference
CREATE Medicines, a clinical-stage biotechnology company specializing in in vivo multi-immune programming, has announced it will participate in the 2026 Jefferies Global Healthcare Conference in London. Senior management, including CEO Daniel Getts and CMO Matthew Maurer, will host one-on-one meetings with investors and potential partners from November 16–19. The company intends to highlight advancements within its four clinical-stage in vivo CAR programs targeting autoimmune diseases and oncology. CREATE leverages a proprietary mRNA-LNP platform designed to program immune cells directly inside the body, claiming the largest clinical dataset in the field with over 80 patients treated.
Tickers: $JEF
Topics: clinical-stage biotechnology in vivo CAR therapy investor conference